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http://dx.doi.org/10.1016/j.ccr.2014.03.020SUMMARYAnchorage of tissue cells to their physical environment is an obligate requirement for survival that is lost in
mature hematopoietic and in transformed epithelial cells. Here we find that a lymphocyte lineage-restricted
transcription factor, Aiolos, is frequently expressed in lung cancers and predicts markedly reduced patient
survival. Aiolos decreases expression of a large set of adhesion-related genes, disrupting cell-cell and
cell-matrix interactions. Aiolos also reconfigures chromatin structure within the SHC1 gene, causing
isoform-specific silencing of the anchorage reporter p66Shc and blocking anoikis in vitro and in vivo. In
lung cancer tissues and single cells, p66Shc expression inversely correlates with that of Aiolos. Together,
these findings suggest that Aiolos functions as an epigenetic driver of lymphocyte mimicry in metastatic
epithelial cancers.INTRODUCTION
Epigenetic dysregulation and instability occur at the earliest
steps of tumorigenesis and accompany every stage of cancer
progression. Consequent activation and/or silencing of tumor
related genes confers premalignant epithelial cells with the
capacity for unrestrained proliferation, resistance to cell death,
evasion from immune destruction, and progression to frank
malignancy (Mehlen and Puisieux, 2006; Timp and Feinberg,
2013; Valastyan and Weinberg, 2011). Despite its importance,Significance
Epigenetic dysregulation is now believed to drive all stages o
However, specific epigenetic factors that broadly reprogram
spread—cellular behaviors which are chiefly responsible for c
that carcinoma cells co-opt a hematopoietic factor required f
repression of SHC1 and other genes. These findings have bro
certain hematopoietic characteristics.specific epigenetic mechanisms by which evolving tumor cells
acquire metastatic potential are poorly understood. In particular,
processes by which widespread transcriptional reprogramming
endow epithelial cells with hematopoietic characteristics allow-
ing metastatic behavior are not clear.
Aiolos (encoded by IKZF3) is amember of the Ikaros zinc finger
family, the expression of which is normally restricted to lymphoid
cells (Morgan et al., 1997). Aiolos exerts broad changes in gene
expression patterns, in large part through the recruitment of
chromatin modifiers such as the nucleosome remodeling andf tumorigenesis in association with key genetic mutations.
cells to allow anchorage independence and metastatic
ancer mortality—are poorly studied. In this report, we find
or lymphopoiesis to survive anchorage deprivation through
ad implications for the ability of epithelial tumors to acquire
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Aiolos and p66Shc in Metastasisdeacetylase (NuRD) complex (Kim et al., 1999; Koipally et al.,
1999). During lymphocyte development, Aiolos is first detected
in pro-B and pro-T cells and is upregulated as these cells prog-
ress to pre-B and double positive CD4/CD8 cells, reaching
maximum expression in mature, activated B and T cells (Wang
et al., 1998). Aiolos facilitates the transition from pre-BCR-driven
proliferation to differentiation and immunoglobulin light chain
rearrangement, and plays important roles in late stages of B
and T lymphocyte development (Ma et al., 2008; Mandal et al.,
2009; Quintana et al., 2012; Reynaud et al., 2008; Thompson
et al., 2007). Notably, this developmental stage also coincides
with a sustained loss of lymphocyte adhesion to its matrix-rich
microenvironment, which is required for lymphocyte entry into
the blood system and subsequent circulation to other organs
(Glodek et al., 2003).
Aiolos expression is also altered in both solid and liquid
tumors. Aiolos is highly expressed and may promote survival in
B cell leukemia and certain lymphomas; conversely, Aiolos is
absent in acute lymphoblastic leukemia (Antica et al., 2008; Billot
et al., 2011; Duhamel et al., 2008; Holmfeldt et al., 2013; Niebuhr
et al., 2013; Romero et al., 1999). Furthermore, Aiolos has been
detected in multiple malignant solid tumor cell lines including
MCF-7, SW480, HEK, PC3, and HeLa (Billot et al., 2010). In the
breast cancer cell line BT474, ectopic expression of Aiolos
results from a fusion event leading to its transcriptional control
by the VABP promoter (Edgren et al., 2011). In addition, a broad
bioinformatic analysis of the human transcriptome in normal and
abnormal tissues revealed upregulation of Aiolos in some breast
cancers (Kilpinen et al., 2008). These reports suggest that Aiolos
may be aberrantly expressed in some solid tumors; however, the
functional consequence of Aiolos expression in carcinomas is
completely unknown. Given the involvement of Aiolos in hemato-
poietic cell development, we hypothesized that Aiolos may pro-
mote the ability of cancer cells to survive in an unanchored state.
Here, we study the molecular and clinical consequences of Aio-
los expression by lung cancers.
RESULTS
Aiolos Expression Correlates with Poor Prognosis in
Human Lung Cancer
We studied Aiolos expression in 116 non-small cell lung cancers
(NSCLC), 17 small cell lung cancers (SCLC), and 7 tumor-adja-
cent normal lung tissues, using immunohistochemical (IHC) ana-
lyses. Normal lung epithelial cells in tumor-adjacent lung tissues
and stromal cells in lung cancer tissues did not express Aiolos.
Lymphocytes in folliculi lymphaticus exhibited strong Aiolos
staining (Figure 1A), consistent with previous reports (Wang
et al., 1998), supporting antibody specificity. Both NSCLC (ade-
nocarcinomas and squamous cell carcinomas) and SCLC cells
expressed Aiolos to varying degrees; many Aiolos-positive
NSCLC cells and all Aiolos-positive SCLC cells exhibited nuclear
localization of Aiolos (Figures 1B–1D). Quantification of staining
on a scale of 0 to 8.0 revealed significantly higher expression
of Aiolos in SCLCs than NSCLCs (Figure 1E). Of note, SCLC is
associated with an extremely poor prognosis (median survival <
2 years) owing to its strong tendency to disseminate early and
present with established metastatic foci (Fischer and Arcaro,
2008; Jackman and Johnson, 2005). Indeed, all 13 SCLC sub-576 Cancer Cell 25, 575–589, May 12, 2014 ª2014 Elsevier Inc.jects with available survival data had high Aiolos staining scores
(>4.0) and low survival rates (median survival 15 months; Table
S1 available online). Thus, the expression level of Aiolos corre-
lates inversely with overall prognosis between histologic sub-
types of lung cancers.
To more closely assess the prognostic significance of Aiolos,
we examined expression levels in resected NSCLC tumors
from subjects with known clinical outcomes. Subjects with early
stage disease (stage I–II, n = 67) whose tumors had low Aiolos
expression levels (staining scores 0–4.0, n = 27) had strikingly
longer survival times than those whose tumors had high expres-
sion levels (staining scores 4.1–8.0, n = 40), with median sur-
vivals of 71 months (low Aiolos) versus 33 months (high Aiolos,
p = 0.0003). Of 65 subjects with stage IIIA disease, median
survivals were 42 months with low Aiolos staining scores (n =
35) and 11 months with high Aiolos scores (n = 30, p < 0.0001).
The survival rate of the high Aiolos expressors is poor and similar
to that for extensive-stage disease SCLC. In a Kaplan-Meier
model, Aiolos protein expression was a strong predictor of
survival rates in patients with stage I or II lung cancer (hazard
ratio 2.95, CI 1.63–5.32, Figure 1F) and in those with stage IIIA
disease (hazard ratio 11.26, CI 5.53–22.90, Figure 1G). Aiolos
staining intensity did not correlate with age, TNM status, smok-
ing history, or sex (Tables S2–S4). These results indicate that
the hematopoietic lineage protein Aiolos is frequently expressed
in lung cancers and its high expression level correlates with
extremely poor survival rates in human lung cancer.
Aiolos Downregulates Cell Adhesion Genes
To explore the effect of Aiolos on established cancer cells, we
expressed Aiolos in A549 cells, a lung carcinoma cell line
that does not express endogenous Aiolos, and analyzed the
resultant expression profile using a microarray platform. Func-
tional classification of differentially expressed genes was
performed, revealing ontologic gene groupings with high fold-
enrichment and low false discovery rates. Within these enriched
functional groups, two gene trees that significantly changed
expression levels (>2-fold in either direction) after Aiolos/IKZF3
overexpression were identified. Tree 1 included 270 downregu-
lated genes and tree 2 contained 267 upregulated genes upon
Aiolos overexpression (Figure 2A). Functional groups most
commonly downregulated represented genes that control
cellular adhesion, including extracellular matrix-receptor inter-
acting proteins, focal adhesion proteins, actin cytoskeleton
regulating proteins, and cell adhesion molecules, with significant
downregulation of adherens, tight, and gap junction proteins,
indicating a broad repression of cell-matrix and cell-cell adhe-
sion machinery. Individual Aiolos-regulated genes and sub-
groups of different molecular pathways are shown in Tables
S5, S6, and S7.
We confirmed Aiolos-dependent differential transcription of
12 genes identified in the microarray analysis including downre-
gulation of CLDN1, CLDN2, ITGB3, ITGB6, ITGAV, ITGA5, and
VCAM1, which play important roles in mediating cell-matrix
and cell-cell adherence, and upregulation of SYK, which partic-
ipates in pre-B signaling and promotes tumor metastasis upon
ectopic expression (Sung et al., 2009), and TNFSF10, CXCR4,
FOS, and PTPRR, which also promote cancer metastasis (Fig-
ure 2B). To confirm the role of Aiolos in gene regulation, we
Figure 1. Aiolos Is Expressed in Lung Cancer
Cells and Predicts Mortality
(A–D) IHC staining with anti-Aiolos was performed
on seven normal lung tumor adjacent tissues, 116
NSCLC, and 17 SCLC specimens. Scale bars
represent 20 mm. Representative fields show positive
Aiolos staining in B lymphocytes in folliculi lympha-
ticus (A), lack of Aiolos staining in normal lung
epithelial cells (B), moderate Aiolos staining in
NSCLC cells (C), and strong Aiolos staining in SCLC
cells (D).
(E) Semiquantitative scoring of Aiolos staining
showed significantly stronger staining in SCLC than
NSCLC (p < 0.05). Error bars represent SD.
(F and G) Kaplan-Meier survival rates for 67 subjects
with stage I–II NSCLC disease and 65 subjects with
stage IIIA NSCLC disease with low (0–4.0 staining
scores, blue lines; n = 27 for stage I–II; and n = 35 for
stage IIIA), versus high (4.1–8.0 staining scores, red
lines; n = 40 for stage I–II; and n = 30 for stage IIIA)
Aiolos expression were compared. Median survivals
were 71 months (low Aiolos) versus 33 months (high
Aiolos) for stage I–II (p = 0.0003) and 42 months (low
Aiolos) versus 11 months (high Aiolos) for stage IIIA
(p < 0.0001).
See also Tables S1–S4.
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Aiolos and p66Shc in Metastasisstudied H1155 cells, a NSCLC cell line that expresses endoge-
nous Aiolos. Knockdown of Aiolos in these cells caused recip-
rocal changes in expression levels of these genes compared
with expression of Aiolos in A549 cells (Figure 2B).
To further study whether adhesion-related genes are regu-
lated directly by Aiolos, we determined the in vivo binding status
of Aiolos within genomic loci of four Aiolos-repressed genes
(CLDN1, CLDN2, ITGA5, and ITGAV) using chromatin immuno-
precipitation (ChIP). Cis-regulatory elements identified byDNase
I hypersensitive sites, as reported in the ENCODE database, and
potential Aiolos binding consensus sites were analyzed for
Aiolos association (Figure 2C). ChIP was performed in A549 cells
expressing Aiolos-FLAG. All four genes analyzed contained
Aiolos consensus sites that were occupied by Aiolos (Figure 2C).
These data suggest that Aiolos directly regulates key cell-matrix
and cell-cell adhesion-related genes.
Aiolos Disrupts Cell-Cell and Cell-Matrix Adhesion
The shift in epithelial gene expression profile induced by Aiolos is
consistent with its physiologic role in lymphocytes preparing for
release into the circulation. Notably, we observed major differ-
ences in A549 cell morphology between control cells and
Aiolos-expressing cells in regular two-dimensional culture.
Whereas control cells spread well and grew as clusters, Aio-
los-expressing cells appeared rounded and exhibited fewer
cell-cell interactions (Figure 3A). This morphological change is
consistent with the decrease in expression of tight junctional
proteins including Claudin 1, Claudin 2, and Occludin following
Aiolos expression. Expression of E-cadherin was not affected;
however, E-cadherin redistributed away from the cell periphery,
indicating disruption of adherens junctions (Figure 3B). These
data demonstrate that Aiolos may disrupt intercellular junctions
through specific repression of key adhesion proteins.
We then tested the effect of Aiolos expression on adherence of
lung cancer cells to fibronectin, a major extracellular matrix
component in lung and tumor stroma. In replating experiments,
Aiolos expression dramatically decreased the number of A549
cells adherent to fibronectin (Figure 3C). Conversely, knockdown
of Aiolos or overexpression of a dominant negative form of Aiolos
(DAiolos/IKZF3, lacking the DNA-binding domain (Caballero
et al., 2007)) significantly increased the adhesion of H1155 cells
to fibronectin (Figure 3C). These data are consistent with the
downregulation by Aiolos of genes involved in at least three
major fibronectin receptors, a4b1, a5b1, and avb3 (Table S5).
However, SCLC cells (H209, H69), which float in culture, do
not adhere following Aiolos knockdown (data not shown) despite
increases in integrin and claudin gene expression (Figure S1A).
Thus, SCLC cells have a more profound adhesion defect andFigure 2. Aiolos Expression Downregulates Cell Adhesion Genes
(A) Functional profiling of genes differentially expressed between control A549 cell
genes upregulated and 270 genes downregulated by Aiolos. Representative Aiolo
under each molecular pathway (right).
(B) Quantitative RT-PCR was performed to confirm the transcriptional change of
Aiolos/IKZF3-expressing A549 cells and control or Aiolos/IKZF3 shRNA-expres
GAPDH.
(C) ChIP was performed in A549 cells transfected with Aiolos/IKZF3 or vector. Ge
sites; red starsmark siteswith Aiolos consensus sequences. Bar graphs show fold
See also Tables S5, S6, and S7.may lack other proteins not under Aiolos control but which are
necessary for firm anchorage. Aiolos expression had no effect
on cell proliferation or invasiveness and caused a slight decrease
in cell motility, as evaluated by bromodeoxyuridine incorpora-
tion, Boyden chamber, and wound healing assays (Figures
S1B–S1D).
Aiolos Promotes Anchorage Independence
Similar to hematopoietic cells, metastatic cancer cells are able
to survive in suspension and thus bypass anoikis, a form of
apoptosis triggered by loss of anchorage to substratum. This
led us to ask whether Aiolos is able to relax cellular anchorage
requirements. We found that transient expression of Aiolos by
primary endothelial cells, which are highly sensitive to anoikis,
effectively blocked anoikis (Figure 3D). We then examined
the effect of Aiolos on anchorage-independent proliferation.
We expressed Aiolos in A549 cells and found that Aiolos signifi-
cantly increased anchorage-independent growth in soft agar
(Figure 3E).
As a third test of anchorage sensing, we studied the ability of
MCF-10Acells to formacinus-like spheroids in three-dimensional
basement membrane gels, which requires loss of inner cell mass
through anoikis (Debnath et al., 2002; Han et al., 2008). Whereas
control cells developed intowell-formed hollow spheroids, Aiolos
expression resulted in disrupted acinus formation with luminal
filling and lack of polarity (Figure 3F). These results indicate that
Aiolos promotes anchorage independence in primary endothelial
cells, immortalized epithelial cells, and transformed cancer cells.
Thus besides decreasing adhesion mechanisms, Aiolos protects
cells from anoikis following loss of anchorage.
Anchorage independence is essential for survival of circulating
cancer cells during metastasis (Valastyan and Weinberg, 2011).
To examine the effect of Aiolos expression on metastatic capac-
ity in vivo, we injected A549 cells into the tail vein of BALB/C
nudemice. Aiolos-expressing A549 cells caused lethality in eight
of eight mice by 77 days, with a median survival of 48 days (Fig-
ures 3G and 3H). In all cases, death was accompanied by a
heavy lung metastatic burden, verified by histologic examination
(Figure 3H). Mice injected with control A549 cells had longer
survival times, with only one of eightmice dying from lungmetas-
tases by 77 days. Therefore, in parallel with loss of anoikis
in vitro, ectopic expression of Aiolos promotes metastatic ca-
pacity of lung cancer cells in vivo.
We expanded our analysis to include solid tumor cell lines
from breast, liver, and colon tissues, and found Aiolos to be ex-
pressed in five of ten cell lines examined (Figure S1E). Further-
more, Aiolos expression correlated with the reported ability of
these cells to metastasize in nude mice with only one exceptions and Aiolos/IKZF3-expressing A549 cells. Double-headed arrows indicate 267
s-induced (red) and Aiolos-repressed genes (green) are listed vertically (left) and
indicated genes identified in the microarray. RNA was purified from control or
sing H1155 cells. Relative expression is shown as fold differences relative to
ne names are indicated at right. Vertical lines indicate DNase I hypersensitive
enrichment of Aiolos binding. Themean ± SDof three determinations is shown.
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Figure 3. Aiolos Promotes Cell Detachment, Anchorage Independence, and Lung Metastasis
(A) Phase-contrast micrographs of A549 cells expressing vector or Aiolos. Scale bars represent 40 mm.
(B) Immunofluorescence and immunoblot were performed to examine the localization of E-cadherin (left two panels) and expression level (right panel) in Aiolos-
expressing A549 cells. Scale bars represent 20 mm.
(C) Aiolos/IKZF3-expressing A549 cells, Aiolos/IKZF3 shRNA-expressing H1155 cells, or dominant-negative Aiolos (DIKZF3)-expressing H1155 cells were plated
on fibronectin-coated plates. After 15 min, attached cells were counted. Scale bars represent 200 mm. Bar graph below shows number of adherent cells. Mean ±
SD of three duplications is shown.
(D) HUVEC cells were transduced with Aiolos/IKZF3. Cell death was assessed after 16 hr under attached or floating conditions. *p < 0.05 from vector attached
conditions; yp < 0.05 from vector floating conditions. Error bars represent SEM.
(E) A549 cells were transduced as indicated, allowed to grow in soft agar for 4 weeks, and colonies counted. Error bars represent SD (n = 3).
(F) Phase-contrast micrographs of control and Aiolos/IKZF3-expressing MCF-10A acini cultured on Matrigel for 18 days. Scale bars represent 15 mm.
(G) A549 cells expressing empty vector or Aiolos/IKZF3were injected into the tail veins of 6-week-old female BALB/C nudemice. Survival curve is shown; survival
between groups was different, p < 0.001.
(H) Representative hematoxylin and eosin stain of lungs from mice injected with vector control and Aiolos/IKZF3-expressing A549 cells. Scale bars represent
50 mm.
See also Figure S1 and Table S8.
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Aiolos and p66Shc in Metastasis(Table S8). Consistently, knockdown of Aiolos in these Aiolos-
expressing cells also lead to increased adhesion (Figure S1F).
To further correlate these findings with human data, The Cancer
Genome Atlas was interrogated for breast cancer outcomes.
Analysis of this data set revealed that high Aiolos/IKZF3 expres-
sion correlates with poor survival rates in breast cancer
(Figure S1G). In total, these data suggest that Aiolos may be of
general significance to anchorage mechanisms in tumors other
than lung cancers.
Expression of Aiolos Negatively Correlates with p66Shc
in Human Lung Cancers
Of particular note given the prominent effects of Aiolos in pro-
moting anchorage independence, we observed that the adaptor
protein Shc was downregulated 2.3-fold by Aiolos expression.
SHC1 contains tandem promoters that are thought to indepen-
dently control p52Shc and p66Shc transcription (Figure 4A),
although very little is known about control of either promoter
(Ventura et al., 2002). p66Shc is required for anoikis and functions
as a powerful metastasis suppressor in mice, whereas the
shorter p52Shc does not (Ma et al., 2010). We found that expres-
sion of Aiolos in A549 cells selectively repressed p66Shc but not
p52Shc expression (Figure 4A). Transient expression of Aiolos
also selectively decreased p66Shc protein levels in A549,
HepG2, and MDA-MB-231 cells, confirming an inhibitory effect
of Aiolos on p66Shc expression (Figure 4B). However, knock-
down of endogenous Aiolos did not restore p66Shc expression
in SCLC (H209, H69, and H82) as well as NSCLC (H1155) or
non-lung carcinoma (Hep3B and MCF-7) cell lines (Figure S2A).
Accordingly, knockdown of Aiolos did not increase sensitivity to
anoikis in H209, H69, and H82 lung cancer cells (Figure S2B).
Thus, although Aiolos is sufficient to repress p66Shc, it does not
appear to be necessary in established cancer cells. To study
this effect further, A549 cells were stably transfected with an
inducible Aiolos transgene. Upon induction of Aiolos by doxycy-
cline treatment for 8 hr, p66Shc protein levelsmarkedly decreased;
however, removal of doxycycline for 8 subsequent days caused
early loss of Aiolos expression but no recovery of p66Shc levels
(Figure S2C). These results indicate that Aiolos may be necessary
for the initiation but not the maintenance of p66Shc silencing.
In strong support of p66Shc repression by endogenously
expressed Aiolos, we noted in a panel of 18 human cell lines of
diverse origin a strict correlation between the expression of
Aiolos and repression of p66Shc (Figures 4C and 4D) but
not p52Shc (data not shown). In contrast, all cells without detect-
able Aiolos expression retained p66Shc expression (Figures 4C
and 4D).
To assess whether p66Shc is commonly repressed in lung
cancer, we screened 207 human lung epithelial cell lines for
expression of p66Shc. Normal lung epithelium consisted of
human bronchial epithelial cells (HBEC, n = 30) and small airway
epithelial cells (HSAEC, n = 29). Expression of p66Shc was robust
and not different between small and large airway epithelium (p >
0.05). Cells derived from lung cancers (n = 148), however, had
significantly reduced expression compared with normal lung
epithelium (p < 0.001; Figure 4E). Notably, p66Shc expression
was significantly lower in SCLC than in NSCLC, and each group
was decreased compared to nonmalignant human bronchial
epithelium (p < 0.001; Figure 4E). Expression at the level of pro-tein in a subset of cells confirmed consistently robust levels of
p66Shc in normal endothelial or lung epithelial cells (Figure 4F).
In contrast, p66Shc protein levels were diminished in most
NSCLC and SCLC cell lines, despite persistence of p52Shc
expression. This expression pattern for p66Shc is opposite from
that which we found for Aiolos and suggests that repression by
Aiolos is biologically relevant.
To define the correlation between Aiolos and p66Shc in individ-
ual primary tumors, we used IHC to examine the expression
levels of Aiolos and p66Shc in serial sections of the previously
characterized NSCLC lung cancer samples. Tumors with signif-
icant levels of staining for Aiolos showed low levels of p66Shc
staining; conversely, surrounding lung parenchyma was nega-
tive for Aiolos but positive for p66Shc (Figure 4G). When intra-
tumoral staining was quantified, a highly significant negative
correlation was found between Aiolos and p66Shc expression
in both stages I–II (r2 = 0.451; p < 0.0001) and IIIA (r2 = 0.719;
p < 0.0001) tumors (Figures 4H and 4I). Accordingly, low
p66Shc expression correlated with worse survival rates in both
stage I/II and IIIA groups (Figures 4J and 4K). Median survivals
in subjects with stage I–II disease were 22 months for low
and > 80 months for high p66Shc staining (p < 0.0001). Median
survivals in subjects with stage IIIA disease were 11 months for
low and 42 months for high p66Shc staining (p < 0.0001).
Because of limitations associated with serial section analysis
and cell-to-cell heterogeneity in protein expression within
tumors, we sought more definitive evidence for biologically rele-
vant repression of p66Shc by Aiolos in human lung cancers
through single cell analysis. Single cancer cells were isolated
from four freshly dispersed human NSCLC tumors for single
cell RT-PCR. Expression of Aiolos/IKZF3, p66Shc, KRT19 (cyto-
keratin 19, a biomarker for NSCLC cells) andGAPDHwere deter-
mined in a single PCR reaction. Figure 4L shows examples of
capillary electropherograms for the four possible qualitative
patterns (±Aiolos/IKZF3, ±p66Shc). A total of 198 cells isolated
from four human lung cancer tissues expressing KRT19 and
GAPDH were further analyzed. Cancer cells purified from tumor
1 expressed p66Shc but not Aiolos/IKZF3, whereas the majority
of cancer cells isolated from the other three tumors expressed
Aiolos/IKZF3 but repressed p66Shc (Table S9). Quantification
of transcript levels revealed a negative correlation between
Aiolos/IKZF3 and p66Shc expression (r2 = –0.239; p < 0.001; Fig-
ure 4M). This correlation appeared biphasic, suggesting that at
the single cell level Aiolos controls a binary decision, strongly
repressing p66Shc when expressed above a certain threshold
level and becoming permissive below this level. Altogether,
these results indicate that expression of endogenous Aiolos
strongly represses p66Shc in multiple carcinomas in vitro and in
tumors and single cancer cells in vivo.
Aiolos Confers Anoikis Resistance through p66Shc
Repression
To assess whether Aiolos abrogates anchorage dependence
through p66Shc repression, we re-expressed p66Shc in Aiolos-
transfected primary endothelial cells, A549 cells, and MCF-10A
cells. Indeed, re-expression of p66Shc completely restored
anoikis in primary endothelial cells (Figure 5A), decreased
anchorage-independent growth of A549 cells in soft agar to
baseline levels (Figure 5B), and restored the ability of MCF-10ACancer Cell 25, 575–589, May 12, 2014 ª2014 Elsevier Inc. 581
(legend on next page)
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Figure 5. Aiolos Confers Anchorage Inde-
pendence through p66Shc Silencing
(A) HUVECs were transduced with Aiolos/IKZF3
or both Aiolos and p66Shc as indicated. Cell death
was assessed after 16 hr under attached or floating
conditions. *p < 0.05 from vector attached condi-
tions; yp < 0.05 from vector floating conditions.
Error bars represent SEM.
(B) A549 cells were transduced as indicated,
allowed to grow in soft agar for 4 weeks, and col-
onies counted. Error bars represent SD (n = 3).
(C) MCF-10A cells were transduced as indicated
and plated in Matrigel. Phase contrast and confocal
midpoint slices of DAPI stained acini are shown.
Scale bars represent 15 mm.
(D) Immunoblots of MCF-10A cells for Shc, Aiolos,
and actin under conditions shown as in (C).
See also Figure S3.
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Aiolos and p66Shc in Metastasisto form differentiated spheroids (Figures 5C and 5D). These
results demonstrate that Aiolos represses p66Shc expression
and thus promotes anchorage-independent behavior, offering
an explanation for the poor prognostic association of Aiolos
with lung cancer mortality rates.
To assess the specificity of this effect for Aiolos, we tested the
expression of other Ikaros family members including Ikaros
(IKZF1), Helios (IKZF2), Eos (IKZF4), and Pegasus (IKZF5) in
normal endothelial and epithelial cells and multiple cancer cell
lines. Surprisingly, Helios, Pegasus, and Eos were expressed
in all 18 cell lines analyzed (Figure S3). The significance of this
broad expression pattern is not clear, although we did not find
any correlation with p66Shc repression. Ikaros is structurally
most similar to Aiolos and was expressed in only four cell lines
(Figure S3). Three of these cell lines also expressed Aiolos andFigure 4. Aiolos Negatively Correlates with p66Shc Expression
(A) Semiquantitative RT-PCR was performed for p52Shc and p66Shc on control or Aiolos/IKZF3-expressing A
mRNA transcripts for SHC1. Shaded areas are 50 and 30 untranslated sequences. Arrows show location of
dilutions of cDNA.
(B) Transient expression of Aiolos/IKZF in A549, MDA-MB-231, and HepG2 cells downregulated p66Shc ex
(C and D) Expression of Aiolos/IKZF3 and p66Shc is shown for normal (HV, HBec) and lung cancer (C) or brea
(E) Expression of p66Shc was assessed from a probe specific for the Shc CH2 domain. Log base 2 of the signa
(p < 0.001) in NSCLC than normal bronchial epithelial cells and lower (p < 0.001) in SCLC than NSCLC or n
(F) Immunoblot of Shc in normal (top panel), NSCLC (middle panel), and SCLC (lower panel) cells showing
(G) IHC for Aiolos and p66Shc was performed on 105 lung specimens. Representative fields show lack of Ai
staining in intra-alveolar mononuclear cells, compared with strong staining in malignant cells. Antibodies
malignant cells in the center of the field are negative for p66Shc staining.
(H and I) Semiquantitative scoring was performed and Aiolos scores were correlated with p66Shc scores in st
0.719, p < 0.0001) tumors.
(J and K) Kaplan-Meier survival curves based on p66Shc staining for patientswith stage I–II (J) and stage IIIA (K
disease were 22months for low and > 80months for high p66Shc staining (p < 0.0001). Median survivals in sub
and 42 months for high p66Shc staining (p < 0.0001).
(L) Representative capillary electropherograms showing PCR products of Aiolos/IKZF3, p66Shc, GAPDH, a
(M) Quantitative analysis was performed to show the correlation of Aiolos/IKZF3 and p66Shc. Each dot repr
See also Figure S2 and Table S9.
Cancer Cell 25, 575–repressed p66Shc, and one (HCT-8) ex-
pressed Ikaros but not Aiolos, with weaker
but distinct expression of p66Shc (Fig-
ure 4D). While it is possible that Ikaros
has repressive effects on p66Shc similar
to Aiolos, Aiolos appears to be morecommonly expressed and correlates more strongly with p66Shc
repression across all cell lines.
Aiolos Represses p66Shc Transcription by Disrupting
Long-Range Enhancer-Promoter Interactions
We then explored the mechanism by which Aiolos silences
p66Shc. Using bisulfite sequencing, we detected variable DNA
methylation of the p66Shc promoter region in SCLC cells (Figures
S4A and S4B). ChIP analyses to scan 14 regions along the SHC1
gene for histone marks revealed decreased association of acti-
vating histones (H3K9acetyl, H3K4me2, and H3K4me3) and
enrichment of repressing histones (H3K9me2) in the p66Shc pro-
moter region in SCLC cells, indicating epigenetic silencing of
p66Shc (Figures S4C and S4D). Of note, repressive histones
were enriched primarily in a 3.5 kb region between the two549 cells. Upper: splicing diagram of two separate
PCR primers. Lower: PCR products of serial 3-fold
pression by immunoblot.
st, liver, and colon cancer (D) cell lines as indicated.
l strength is shown. Expression of p66Shc was lower
ormal cells.
relative expression of 66, 52, and 46 kDa forms.
olos staining in lung parenchymal cells with variable
to p66Shc variably stain alveolar septal wall cells;
age I–II (H; r2 = 0.451, p < 0.0001) or stage IIIA (I; r2 =
) disease.Median survivals in subjects with stage I–II
jects with stage IIIA disease were 11months for low
nd KRT19.
esents one cancer cell.
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Aiolos and p66Shc in Metastasispromoters in SCLC cells, suggesting a chromatin domain specif-
ically controlling p66Shc expression. Further ChIP studies
revealed the occupancy of this region, including the p66Shc
promoter, by endogenous Aiolos in SCLC cells, as well as by
transfected Aiolos in A549 cells (Figure 6A). Transient expression
of DAiolos/IKZF3 failed to repress p66Shc transcription (Fig-
ure 6B), indicating that Aiolos requires direct DNA binding,
possibly to this upstream cis-regulatory element, to silence
p66Shc transcription.
Alignment of human, mouse, and rat p66Shc genes revealed
a 113 bp conserved sequence residing within the noncoding
region 2.1 kb upstream from the p66Shc transcriptional start
site (TSS), marking one potential cis-regulatory enhancer (site
4, Figure 6C). As a second method to screen for enhancers,
we used ChIP to scan the SHC1 gene for H3K27ac and
H3K4me1, modified histones that are frequently associated
with human enhancers (Heintzman et al., 2007; Rada-Iglesias
et al., 2011). We identified two regions enriched with H3K27ac
in normal bronchial epithelium, again within the putative
p66Shc-regulatory domain (sites 2 and 5, Figure 6C). Site 5 but
not site 2 was co-occupied by H3K4me1. In contrast, in H209
SCLC cells, only the H3K27ac modification was recovered
from site 2 and neither modification from sites 4 or 5 (Figure 6C).
We then tested the function of sites 2, 4, and 5 (renamed E1,
–3,474 to –3,311; E2, –2,132 to –2,019; and E3, –779 to –610
from the p66Shc TSS) as potential enhancers of the p66Shc pro-
moter. Luciferase reporters transfected into both HUVEC and
Hbec, which express p66Shc, showed basal promoter activity
contained within the –508 to +101 fragment, as expected (Fig-
ure 6D). Serial extensions of this fragment demonstrated that
inclusion of E2+E3 but not E3 alone significantly enhanced basal
promoter activity, and inclusion of E1 had no further effect. Of
significance, the basal promoter had equivalent activity when
transfected into H69 and H209 SCLC cells, but no enhancement
was observed upon inclusion of E1, E2, or E3 (Figure 6D).
Because these cells express no detectable p66Shc, enhancer
rather than promoter activity appears to determine functional
p66Shc expression. Cotransfection of wild-type but not
DAiolos/IKZF3 with the luciferase reporter fully repressed
enhancer activity (Figure 6E), indicating that DNA binding is
necessary for Aiolos to inhibit enhancer activity. Three Aiolos
consensus sites were identified within E2 and one within the
p66Shc promoter. Whereas mutation of each of these single
binding sites in a luciferase reporter had no effect (Figure S4E),
mutation of all three sites within E2 significantly blocked
Aiolos-dependent inhibition of enhancer activity (Figure 6E).
Furthermore, EMSA with supershift showed direct binding ofFigure 6. Aiolos Directly Regulates p66Shc Transcription
(A) ChIP demonstrates association of Aiolos-Flag in transfected A549 cells with r
Aiolos with regions 2–7 in H209 SCLC cells.
(B) p66Shc expression was examined in A549 cells expressing wild-type Aiolos/IK
(C) ChIP shows distribution of H3K4me1 and H3K27ac histone modifications in
represent SD of three independent chromatin preparations.
(D) Diagram shows serial deletions of the luciferase reporter upstream of the p66
(E) Luciferase reporter studies with the –2,824 to +101 segment containing E2 an
p66Shc promoter enhancement. p66P denotes the p66Shc basal promoter. Triple m
of enhancer activity (top bar). Normalized signals for (D) and (E) represent mean
(F) EMSA shows mobility shift of probe with E2 sequence containing the first two
See also Figure S4.Aiolos to this sequence (Figure 6F). These data support a model
whereby Aiolos suppresses p66Shc transcription through DNA
binding within a cis-regulatory upstream region with consequent
deactivation of p66Shc enhancer function.
Further luciferase studies revealed that in their native posi-
tions, both E2 and E3 were necessary for enhancer activity,
whereas deletion of either abrogated enhancement (Figure 7A).
In contrast, ectopic placement of E2 just upstream of the pro-
moter, in forward or inverted orientation, restored full enhancer
activity, whereas E1 and E3, alone or in combination, had no
effect (Figure 7B). Thus, E2 harbors the principal enhancer
activity for the p66Shc promoter. Because relocalization of E2
to a position adjacent to the promoter obviated the requirement
for E3, E3 may promote physical interactions between E2 and
the p66Shc promoter which are required for promoter activation.
To more directly study the importance of intragenic chromatin
interactions in p66Shc regulation, we used chromosome confor-
mation capture (3C) to examine the physical proximity of
enhancer and promoter elements. In brief, cross-linked chro-
matin was digested with Dpn II, diluted, re-ligated, and long-
range association frequencies were assessed with PCR. When
the p66Shc promoter fragment was used as a PCR anchor, very
strong associations were seen between the p66Shc promoter
and the E1, E2, E3, and p52Shc promoter regions in p66Shc-
expressing normal human bronchial epithelial cells (Hbec; Fig-
ure 7C). With the E1, E2, E3, and p52Shc promoter fragments
as anchors, strong interactions were confirmed between all three
candidate enhancers and both p66Shc and p52Shc promoter
regions, and between the two promoters in Hbec (Figures
S5A–S5D). Such extensive interactions between the five cis-
acting sites are seen in a heat-map representation of cross-link-
ing frequencies across chromatin domains (Figure 7D). Thus in
p66Shc-expressing cells, we detect a higher-order complex con-
taining both promoters and all three candidate enhancers.
In H209 SCLC cells, repression of p66Shc was associated with
persistence of interactions between E1 and the p66Shc promoter
(Figure 7C), and between E3 and E1 (Figures 7D, S5A, and S5B),
consistent with the enrichment of H3K27ac in E1 in H209 cells
(Figure 6C). However, interactions between E2, the p52Shc
promoter, and the p66Shc promoter were lost (Figures 7C, 7D,
S5C, and S5D). Importantly, transient expression of Aiolos by
A549 cells caused delocalization of E1, E2, and the p52Shc
promoter from the p66Shc promoter (Figure 7E), leading to a
chromatin structure resembling that seen in H209 cells. We
next studied the persistence of SHC1 structural remodeling
following transient Aiolos expression using the doxycycline-
inducible model. Eight days after doxycycline withdrawal andegions 4–7, indicated in the upper diagram. Right: similar association of native
ZF3 or DAiolos/IKZF3.
Hbec (p66Shc-expressing) and H209 (p66Shc-nonexpressing) cells. Error bars
Shc TSS; bar graphs show luciferase activity.
d E3. Transient expression of Aiolos/IKZF3, but not DAiolos/IKZF3, abrogated
utation of three Aiolos consensus sites within E2 impaired Aiolos-induced loss
± SD of triplicates.
Aiolos consensus sites, with supershift following anti-Aiolos treatment.
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Figure 7. Aiolos Disrupts E2-p66Shc Pro-
moter Interactions
(A) Luciferase reporter activity is shown with dele-
tion of either E2 or E3.
(B) Ectopic placement of the candidate enhancers
adjacent to the p66Shc promoter was performed as
shown. Mean ± SD of three determinations is
shown.
(C–E) 3C was used to calculate cross-linking
frequency between chromatin segments to assess
proximity in Hbec (p66Shc-expressing, solid circles)
and H209 (p66Shc-nonexpressing, open circles)
cells. Vertical lines representDpn II restriction sites;
arrows indicate PCR primer sites and direction.
Anchor symbols mark anchoring primer for each
data set. Cross-linking frequency between the
p66Shc promoter and other Dpn II-defined seg-
ments is shown in (C). Mean ± SD of 3 independent
chromatin preparations is shown. (D) Heatmaps of
cross-linking frequency in Hbec and H209 cells.
Anchoring primer is listed below, Dpn II-defined
segments numbered as in (C). (E) Cross-linking
frequency is shown using the p66Shc promoter as
anchor in A549 cells transiently expressing Aiolos
(open circles) or vector control (solid circles).
Mean ± SD of three independent experiments is
shown.
(F) Schematic showing formation of a transcrip-
tionally active complex containing p52Shc /p66Shc
promoters and E1–E3 regions. Upon binding of
Aiolos (shaded circles) to E2 and surrounding
regions, the complex is disrupted and p66Shc is
silenced.
See also Figure S5.
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from the p66Shc promoter, whereas the dislocation of E1 from
the p66Shc promoter was reversed (Figure S5E). The stability of
this chromatin reconfiguration with respect to the E2 enhancer
matches the durable silencing of p66Shc after Aiolos knockdown.
These data support a model whereby p66Shc transcription re-
quires long-range physical interaction between the primary
enhancer E2 and the p66Shc promoter. Aiolos associates with
multiple upstream sites including an E2-containing chromatin
domain, altering higher order chromatin structure, disrupting
enhancer-promoter interactions, and silencing p66Shc transcrip-
tion (Figure 7F).
DISCUSSION
Metastatic spread of tumors accounts for the vast majority of
cancer-related deaths; here, we describe an integrated cellular
program that enables transformed epithelium to gain metastatic
properties through lymphocyte mimicry. This process requires
cells to downregulate proteins that constitute cell-cell and cell-
matrix adhesion complexes and in addition, to acquire
anchorage independence. In part, this cellular behavior resem-
bles normal lymphocyte development as pro- and pre-B cell
progenitors prepare to leave the hematopoietic niche. During
this transition, B lymphocytes lose their ability to form sustained586 Cancer Cell 25, 575–589, May 12, 2014 ª2014 Elsevier Inc.adhesions to bone marrow matrix, and are capable of only tran-
sient adhesions as circulating mature cells (Glodek et al., 2003).
Accordingly, this lymphocyte maturation phase is accompanied
by broad shifts in the expression of integrins and other adhesion
proteins, with a preponderance of downregulated adhesion-
related genes moving from the early B through the pro- and
pre-B cell stages to immature B lymphocytes (Hystad et al.,
2007).
Aiolos expression in lymphocytes parallels this progression
and peaks in mature B and T cells. Consequently, loss of Aiolos
results in an increased pre-B population within the bone marrow
environment with diminished recirculating B lymphocytes (Wang
et al., 1998). While temporally correlated with changes in
lymphocyte adhesion properties, it is not clear whether Aiolos
expression directly modulates adhesion-related genes in lym-
phocytes. However, it is particularly striking that a major effect
of ectopic Aiolos expression in lung cancer cells is the repression
of a large number of adhesion-related genes. This shift in expres-
sion profile suggests that Aiolos may generally control a broad
transcriptional program that allows hematopoietic, or in an
abnormal context, epithelial cell departure from a developmental
niche to gain entry into the circulation.
Beyond the loss of durable cell-matrix adhesion, Aiolos may
confer other hematopoietic properties important for the acquisi-
tion of metastatic ability by epithelial cells. First, Aiolos
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Aiolos and p66Shc in Metastasisdownregulates claudins and occludins and disrupts cell-cell
junctions. Epithelial polarity and differentiation are maintained
by intact tight and adherens junctions, and disruption of such
intercellular junctions induces epithelial-to-mesenchymal transi-
tion and metastatic behavior (Derksen et al., 2006; Onder et al.,
2008). Themechanisms linking such loss of polarity to oncogenic
transformation involves changes in gene expression patterns
induced by alterations in Wnt, transforming growth factor b, Hip-
po, and TBX2 pathways (Frisch et al., 2013; Kumar et al., 2011).
Second, whereas release from a solid matrix environment is a
prerequisite for metastatic spread, circulating tumor cells must
also be able to survive such a loss of anchorage, which normally
triggers anoikis (Frisch and Francis, 1994). Accordingly, loss of
junctional integrity has also been shown to suppress anoikis,
which is critical for metastatic capacity (Derksen et al., 2006;
Kumar et al., 2011; Onder et al., 2008). Of importance, Aiolos
also silences p66Shc, a Shc isoform not expressed by hemato-
poietic cells.SHC1 gives rise to both p66Shc and p52Shc, proteins
with divergent cellular functions. p52Shc is recruited to integrins
and couples mitogenic stimulation of Ras and Rac1 to integrin
ligation, thus providing anchorage context to proliferative
signaling pathways (Mainiero et al., 1997; Wary et al., 1996). In
contrast, p66Shc inhibits growth factor signaling, restrains Ras
and Rac1, and induces anoikis (Giorgio et al., 2005; Ma et al.,
2007, 2010; Xi et al., 2010). Whereas p52Shc permits
anchorage-independent growth (Pelicci et al., 1992), p66Shc
enforces anchorage dependence and prevents metastatic
behavior in mice (Ma et al., 2007, 2010). Within the SHC1
gene, we find that Aiolos selectively silences p66Shc but not
p52Shc. Thus, p66Shc represents a critical target for Aiolos-
related silencing in metastatic cancers, confirmed by the ability
of p66Shc to reverse Aiolos-induced anchorage independent
behavior in vitro. However, upon Aiolos knockdown, we also
find that cell-matrix adhesion and the expression of adhesion-
related genes increase, whereas p66Shc remains deeply
silenced. This implies that Aiolos exerts both p66Shc-dependent
and p66Shc-independent effects in its ability to alter anchorage
properties.
A third characteristic of circulating lymphocytes assumed
bymetastatic solid tumors is their ability to home back to specific
vascular and lymphatic beds once in the circulation. In this
regard, it is noteworthy that Aiolos causes a marked induction
of CXCR4, a homing chemokine receptor involved in directing
hematopoietic cells to bone marrow, lymph nodes, lung, and
other vascular beds commonly targeted by metastatic solid
tumors. Although the full significance of this effect has yet to
be explored, CXCR4 expression has been shown to correlate
strongly with both metastatic activity and mortality in breast,
lung, and other carcinomas (Hermann et al., 2007; Jung et al.,
2013; Mu¨ller et al., 2001).
In summary, this study reveals a central mechanism by
which epithelial carcinomas acquire certain hematopoietic
characteristics to gain metastatic ability through abnormal
expression of a key epigenetic modifier required for lymphocyte
development and function. Expression of Aiolos leads to a
molecular form of hematopoietic ‘‘identity theft’’ that allows solid
tumors to mimic cellular behaviors normally involved in lympho-
cyte trafficking during immune surveillance. The high prevalence
of Aiolos expression in human lung cancers and its strong in-verse correlation with the metastasis suppressor p66Shc in pri-
mary tumors and single cancer cells substantiates the clinical




Serial tissue sections were prepared from archived formalin-fixed paraffin-
embedded human lung cancer specimens and quantitative scoring of tissue
sections was performed in a blinded fashion. The percentages of positive cells
and staining intensity were scored separately and contributed to the aggregate
score. The use of all human lung cancer tissues and clinical data was approved
by the Institutional Review Board of Tianjin Medical University. Informed con-
sent was obtained from all patients, and samples were deindentified prior to
analysis. Kaplan-Meier survival curves were analyzed using Mantel-Cox log-
rank tests, and hazard ratios calculated using Mantel-Haenszel tests
(GraphPad Prism 6.02). Human lung cancer cell line expression profiles were
entered under Gene Expression Ominubus accession number GSE32036
(Osborne et al., 2013; Byers et al., 2013). Further details and references are
provided in the Supplemental Experimental Procedures.
Expression Profiling
The expression and functional profiles of genes were compared between A549
cells expressing empty vector and Aiolos/IKZF3 using Agilent SurePrint G3
HumanGene Expression 8x60K v2Microarray (Agilent Technologies). Analysis
of functional profiling of Aiolos-regulated genes was performed using the
Database for Annotation, Visualization, and Integrated Discovery (DAVID)
based on the biological pathways from KEGG (Kyoto Encyclopedia of genes
and genomes) database. Expression profiling for human lung cancer cell lines
was performed using the Illumina Human WG-6 V3 chip on 119 NSCLC, 29
SCLC, 30 HBEC, and 29HSAEC cell lines. Arrays were background-corrected,
quantile-normalized, and log-transformed. Further details and references are
provided in the Supplemental Experimental Procedures.
Anchorage-Independent Cell Behavior
Anoikis was assessed by measuring cell death (DNA fragmentation, Roche)
after 16 hr of culture on cell culture-treated or low attachment plates (Corning).
For anchorage-independent growth, 104 A549 cells were suspended in 0.35%
agarose the poured over 0.6% agar in six-well plates. Colonies were counted
after 4 weeks. To generate acini, MCF-10A cells were grown in reconstituted
basement membrane (Matrigel, BD). All animal procedures were approved
by Animal Care and Use Committee at Tianjin Medical University and conform
to the legal mandates and national guidelines for the care and maintenance of
laboratory animals. Further details and references are provided in the Supple-
mental Experimental Procedures.
Single Cell RT-PCR
Fresh human lung tumor surgical samples were trimmed free of adventitial
tissue, minced, and digested with collagenase to release cancer cells. Single
cancer cells were isolated and transferred into freshly prepared cell lysis buffer
for RT-PCR. Amplification of SHC1(p66), IKZF3, GAPDH, and KRT19 was
performed in a single tube, and products quantified by capillary electropho-
resis. Details of the protocol and sequences of primers used are provided in
the Supplemental Experimental Procedures.
Chromosome Conformation Capture
Cells (13 106) were cross-linked, lysed, and nuclei were digested with Dpn II.
After ligation and subsequent DNA purification, the cross-linking frequencies
between the anchor and test fragments were estimated by PCR reactions rela-
tive to standards. A PCR product from 6 kb upstream of the p66Shc promoter
was ligated at high concentration following Dpn II digestion was used to
generate standards. The cross-linking and ligation efficiencies between
different samples and different experiments were normalized by setting
the highest cross-linking frequency for each experimental series to 1.0. Error
bars represent the SDs from the means from three to five independent exper-
iments as indicated in the figure legends. Experimental details and primerCancer Cell 25, 575–589, May 12, 2014 ª2014 Elsevier Inc. 587
Cancer Cell
Aiolos and p66Shc in Metastasissequences used in this study are provided in the Supplemental Experimental
Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for A549 cell expression
profile data is GSE50812.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and nine tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.03.020.
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